Close
  Indian J Med Microbiol
 

Figure 1: MM MRD sequential gating strategy. (a) Time versus CD38 gate to assess the quality of sample acquisition (b) Singlet gate (FSC-A vs. FSC-H) to exclude doublets (c) NDCE gate (FSC-A vs. SSC-A) to gate only viable events (d) PC gate (CD38 vs. CS138) - broad gate to include all CD38/CD138 positive events (e) Refined PC gate (CD38 vs. CD45) to exclude non-PC events. (f) CD19 versus CD45 plot on refined PC (g) CD19+ CD56− (purple) NPCs and CD19− CD56+ (pink) APCs (h) CD19+ CD81+ NPCs and CD19− CD81− APCs (i) CD27+ NPCs and CD27− APCs (j) lambda restricted APCs (k) Polyclonal NPCs. NDCE = Nondebris cells; MRD = Minimal residual disease; MM = Multiple myeloma; PC = Plasma cell; NPCs = Normal PCs; APCs = Abnormal plasma cell

Figure 1: MM MRD sequential gating strategy. (a) Time versus CD38 gate to assess the quality of sample acquisition (b) Singlet gate (FSC-A vs. FSC-H) to exclude doublets (c) NDCE gate (FSC-A vs. SSC-A) to gate only viable events (d) PC gate (CD38 vs. CS138) - broad gate to include all CD38/CD138 positive events (e) Refined PC gate (CD38 vs. CD45) to exclude non-PC events. (f) CD19 versus CD45 plot on refined PC (g) CD19+ CD56− (purple) NPCs and CD19− CD56+ (pink) APCs (h) CD19+ CD81+ NPCs and CD19− CD81− APCs (i) CD27+ NPCs and CD27− APCs (j) lambda restricted APCs (k) Polyclonal NPCs. NDCE = Nondebris cells; MRD = Minimal residual disease; MM = Multiple myeloma; PC = Plasma cell; NPCs = Normal PCs; APCs = Abnormal plasma cell